Mauro Vitor Mendlowicz

Mauro Vitor Mendlowicz

Auto-generated profile, based on publicly available information

Mauro Vitor Mendlowicz

Universidade Federal Fluminense, Brasil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
WBWilliam Berger
William Berger
MMMauro V. Mendlowicz
Mauro V. Mendlowicz
CMCarla Marques-Portella
Carla Marques-Portella
GKGustavo Kinrys
Gustavo Kinrys
Leonardo FontenelleLeonardo Fontenelle
Leonardo Fontenelle
IFIvan Figueira
Ivan Figueira

22 August 2007 in Journal of Traumatic Stress
Verified
Journal Article
Closed access
PDF file
WBWilliam Berger
William Berger
IFIvan Figueira
Ivan Figueira
AMAna Maria Maurat
Ana Maria Maurat
ÉBÉrika P. Bucassio
Érika P. Bucassio
IVIsabela Vieira
Isabela Vieira
MMMauro V. Mendlowicz
Mauro V. Mendlowicz

24 December 2016 in Archives of Women's Mental Health
Verified
Journal Article
Closed access
PDF file
CTCintia T. Tanaka
Cintia T. Tanaka
WBWilliam Berger
William Berger
AVAlexandre M. Valença
Alexandre M. Valença
ECEvandro S. F. Coutinho
Evandro S. F. Coutinho
GJGirardin Jean-Louis
Girardin Jean-Louis
MMMauro V. Mendlowicz
Mauro V. Mendlowicz

18 April 2022 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
BCBruna Campos
Bruna Campos
VVVitor Vinder
Vitor Vinder
RPRoberta Benitez Freitas Passos
Roberta Benitez Freitas Passos
ECEvandro Silva Freire Coutinho
Evandro Silva Freire Coutinho
NVNorma Cavalcanti Pontilhão Vieira
Norma Cavalcanti Pontilhão Vieira
WBWilliam Berger
William Berger
Background: Most international guidelines suggest that benzodiazepines (BDZs) may be inefficient or iatrogenic in the aftermath of a potentially traumatic event (PTE). The goal of this study was to assess the strength of the evidence on whether the use of BDZs in the aftermath of a PTE negatively affects the incidence and severity of post-traumatic stress disorder (PTSD). Methods: We systematically scrutinized the ISI Web of Knowledge, MEDLINE, SCOPUS, and PTSDpubs electronic databases in addition to citation searching. We included original studies providing data about the development of PTSD in adults after BDZ administration in the aftermath of a PTE. We screened 387 abstracts and selected eight studies for the qualitative synthesis and seven for the meta-analysis. We performed two separate meta-analyses, one for randomized clinical trials (RCTs) and the other for cohort studies. Heterogeneity between studies was evaluated with Higgins I² statistic and tested using the χ². This study was registered at PROSPERO (number 127170). Results: The meta-analysis of the cohort studies showed an increased risk of PTSD in patients who received BDZs compared to those who did not (risk ratio (RR) = 1.53; 95% confidence interval (CI): 1.05–2.23) with a modest heterogeneity among studies ( I2 = 41.8, p = 0.143). Regarding the RCTs, the combined measure revealed a tendency toward an increased severity of the PTSD symptoms (standardized mean difference (SMD): 0.24; 95% CI: 0.32–0.79). Conclusion: The studies reviewed showed a possible harmful effect of BDZs when used immediately after a PTE. However, these conclusions were based on a small number of studies of poor to moderate methodological quality.

1 September 2018 in Psychiatry Research
Verified
Journal Article
Closed access
MGMárcio Gekker
Márcio Gekker
ECEvandro Silva Freire Coutinho
Evandro Silva Freire Coutinho
WBWilliam Berger
William Berger
MLMariana Pires da Luz
Mariana Pires da Luz
AAAlexandre Xavier Gomes de Araújo
Alexandre Xavier Gomes de Araújo
MMMauro Vitor Mendlowicz
Mauro Vitor Mendlowicz

7 October 2013 in Comprehensive Psychiatry
Verified
Journal Article
Open access
AAA.X. Araújo
A.X. Araújo
WBWilliam Berger
William Berger
ECE.S.F Coutinho
E.S.F Coutinho
CMCarla Marques-Portella
Carla Marques-Portella
MLM.P. Luz
M.P. Luz
MMMauro Vitor Mendlowicz
Mauro Vitor Mendlowicz
Purpose: No study has examined the impact of the comorbid Axis I conditions on the quality of life (QoL) of patients with a primary diagnosis of PTSD. Our goal was to investigate the influence of comorbid disorders on the QoL of treatment-seeking outpatients with PTSD. Methods: The diagnoses of PTSD and of the comorbid disorders were established using the SCID-I. The 54 volunteers also completed the Posttraumatic Stress Disorder Checklist – Civilian Version, the BDI, the BAI, the Trauma History Questionnaire, and a socio-demographic questionnaire. Quality of life was assessed by means of the WHOQOL-BREF, a 26-item self-administered scale that measures four domains of QoL: psychological, physical, social, and environmental. Multiple linear regression models were fitted to investigate the relationship between the severity of post-traumatic, mood, and anxiety symptoms; the presence of specific current comorbid disorders and of psychotic symptoms, the number of current comorbid conditions, and a history of child abuse for each of the four domains of QoL, after adjusting for the effect of socio-demographic characteristics. Results: The severity of PTSD symptoms impacted negatively on the psychological and physical domains. The severity of depressive symptoms correlated negatively with QoL in all domains, independently of sex, age, occupation, and marital status. The psychotic symptoms impacted negatively on the environmental domain. A history of child abuse was negatively associated with the psychological and the social domains. Conclusions: The severity of comorbid depressive symptoms is one of the most important factors in the determination of the QoL in patients with PTSD.